Abstract: Provided are a 2-(aryl-2-yl) morpholine and a deuterated derivative thereof, a preparation method therefor and an application thereof. In particular, involved are the use of a compound shown by general formula (V) in the treatment of central nervous system diseases, a deuterated compound thereof, a preparation method of deuterated compound, a pharmaceutical composition containing the deuterated compound, and the use thereof as a TAAR1 agonist in the treatment of central nervous system diseases.

Abstract: Embodiments of the present disclosure provide a display panel comprising a light-emitting element, in which the light-emitting element includes a first electrode layer, a first light-emitting layer, a first buffer layer, a first charge-generating layer, a second buffer layer, a second light-emitting layer, and a second electrode layer; in which the first charge-generating layer includes a first n-type charge-generating layer and a first p-type charge-generating layer, and both of the electron mobility of the first buffer layer and the electron mobility of the second buffer layer are less than the electron mobility of the first n-type charge-generating layer.

Abstract: A floor-type air-conditioning indoor unit and an air conditioner are provided. The indoor unit has a housing, a top air outlet frame and a fan assembly. The housing has an installation port where the top air outlet frame is installed. The top air outlet frame is movable in an up-down direction and has a lower port and a front port. The fan assembly blows airflow from the air inlet to the lower port and out from the front port of the top air outlet frame. One of the top air outlet frame and the housing is provided with a sliding plate extending in the up-down direction, and the other is provided with a sliding groove engaging the sliding plate. A length of the sliding plate is longer than or equal to a maximum trip of the top air outlet frame in the up-down direction.

Abstract: A method includes: when a first virtual address of a first virtual address space is obtained, determining a first entry index address corresponding to the first virtual address; and determining, from a first page table based on the first entry index address, a first target physical address corresponding to the first virtual address. A second entry index address corresponding to a start virtual address of the first virtual address space is greater than or equal to a base address of the first page table, and is less than a sum of the base address of the first page table and a quotient of dividing the start virtual address by a size of a second virtual address space.

Abstract: A method includes: when a first virtual address of a first virtual address space is obtained, determining a first entry index address corresponding to the first virtual address; and determining, from a first page table based on the first entry index address, a first target physical address corresponding to the first virtual address. A second entry index address corresponding to a start virtual address of the first virtual address space is greater than or equal to a base address of the first page table, and is less than a sum of the base address of the first page table and a quotient of dividing the start virtual address by a size of a second virtual address space.

Abstract: A nitrogen-containing fused ring derivative inhibitor, a preparation method therefor and the use thereof. The present invention particularly relates to a compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition thereof, and the use thereof as an NK inhibitor in the treatment of depression, anxiety, schizophrenia, sex hormone-dependent diseases and other related diseases. The various substituents in general formula (I) have the same definition as that in the description.

Abstract: Provided is a modifier of a four-membered ring derivative, a preparation method and application thereof. In particular, provided is a compound represented by the general formula (IX-A), a preparation method thereof, a pharmaceutical composition containing the compound, and a use thereof as a G protein-coupled receptor modulator in the treatment or prevention of central nervous system diseases and/or mental diseases. The definition of each substituents in the general formula (IX-A) is same as the definition in the specification.

Abstract: A floor-type air-conditioning indoor unit and an air conditioner are provided. The indoor unit has a housing, a top air outlet frame and a fan assembly. The housing has an installation port where the top air outlet frame is installed. The top air outlet frame is movable in an up-down direction and has a lower port and a front port. The fan assembly blows airflow from the air inlet to the lower port and out from the front port of the top air outlet frame. One of the top air outlet frame and the housing is provided with a sliding plate extending in the up-down direction, and the other is provided with a sliding groove engaging the sliding plate. A length of the sliding plate is longer than or equal to a maximum trip of the top air outlet frame in the up-down direction.

Abstract: A floor-standing air conditioner indoor unit and an air conditioner are provided. The indoor unit has a housing, a top air outlet frame, a fan assembly and a heat exchanger. The housing has an outer housing and an air duct housing in the outer housing. An air duct is formed in the air duct housing. The air duct housing has a rear air inlet and a front air outlet communicating with the air duct. A lower end of the top air outlet frame is in communication with the air duct. A top air outlet is formed on a front side of the top air outlet frame. The top air outlet frame is mounted on a top of the air duct housing and movable in a vertical direction to allow the top air outlet to extend out of the outer housing or retract into the air duct housing.

Abstract: The present invention relates to an indoleamine 2,3-dioxygenase inhibitor having the structure of formula (I), a preparation method therefor, and an application. The IDO inhibitor is an N?-hydroxyl-N-phenylformamidine derivative, which has a high inhibitory activity on IDO, effectively inhibits IDO activity, and may also be used to inhibit patient immunosuppression. The inhibitor may be widely applied to treat or prevent cancers or tumors, viral infections, depression, neurodegenerative disorders, trauma, age-related cataracts, organ transplant rejection or autoimmune diseases, and has the potential to be developed into a new generation of immunosuppressors.